tlqp-21

TLQP 21 is a VGF-derived peptide. TLQP 21 can protect cerebellar granule cells (CGCs) from serum and potassium deprivation-induced apoptosis and increases energy expenditure and prevents early phase diet-induced diabetes.

[DArg10, DAla20]TLQP-21, also known as a TLQP-21 analogue, functions as a C3aR agonist with an EC50 of 87 nM for β-arrestin recruitment. This compound induces calcium influx and can slightly enhance adrenaline-induced lipolysis, although not significantly. It is applicable for research on inflammatory diseases, metabolic disorders, and neurological disorders.

[DArg10, Aib20]TLQP-21, also known as a TLQP-21 analogue, functions as a C3aR partial agonist and a C3aR functional antagonist (with a β-arrestin recruitment EC50 of 854 nM). It does not exhibit significant calcium ion influx activity or enhanced adrenergic-induced lipolytic activity. This compound is applicable in research concerning inflammatory diseases, metabolic disorders, and neurological conditions.

TLQP 21 acetate is a potent agonist of G-protein-coupled receptor complement-3a receptor 1 (C3aR1). The EC50 values are 10.3 μM for mouse and 68.8 μM for human. TLQP 21 acetate is a VGF-derived peptide with endocrine and extraendocrine properties.

Chronic intracerebroventricular (ICV) injection of a VGF peptide named TLQP-21 increased resting energy expenditure and temperature in mice. Furthermore, in mice fed a high-fat diet, the same peptide prevented the increase in body and white adipose tissue